REGULUS THERAPEUTICS INC.

(RGLS)
  Report
Delayed Nasdaq  -  04:00 2022-08-05 pm EDT
1.610 USD   -5.29%
08/04Regulus Therapeutics Announces Timing for Second Quarter 2022 Financial Results Webcast and Conference Call
PR
07/15REGULUS THERAPEUTICS INC. : Other Events (form 8-K)
AQ
06/29REGULUS THERAPEUTICS INC. : REVERSE SPLIT: 1 of 10
FA
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news
Sector news Bio Therapeutic Drugs
08/05Goldman Sachs Adjusts Price Target for Vertex Pharmaceuticals to $389 From $368, Mainta..
MT
08/05HC Wainwright Raises Vertex Pharmaceuticals Price Target to $300 From $275, Maintains B..
MT
08/05BioNTech, Genmab Expand Cancer Treatment Collaboration to Address Malignant Solid Tumor..
MT
08/05Barclays Adjusts Price Target on Vertex Pharmaceuticals to $307 From $291, Reiterates O..
MT
08/05RBC Raises Price Target on Vertex Pharmaceuticals to $278 From $269, Maintains Sector P..
MT
08/05Genmab, BioNTech Expand Cancer Therapy Collaboration
MT
08/05Genmab, BioNTech Expand Research Partnership for Cancer Treatments
DJ
08/04TRANSCRIPT : Vertex Pharmaceuticals Incorporated, Q2 2022 Earnings Call, Aug 04, 2022
CI
08/04Vertex Pharmaceuticals Reports Higher Q2 Adjusted Profit, Revenue; Lifts 2022 Product R..
MT
08/04Earnings Flash (VRTX) VERTEX PHARMACEUTICALS INCORPORATED Reports Q2 EPS $3.60
MT
08/04Vertex Pharmaceuticals Incorporated Reports Earnings Results for the Second Quarter and..
CI
08/04Vertex Pharmaceuticals Incorporated Reports Unaudited Intangible Asset Impairment Charg..
CI
08/04EARNINGS REACTION HISTORY : Vertex Pharmaceuticals, 50.0% Follow-Through Indicator, 2.4% S..
MT
08/04Goldman Sachs Increases Regeneron Pharmaceuticals' Price Target to $796 From $790, Main..
MT
08/04UBS Adjusts Gilead Sciences Price Target to $65 From $63, Maintains Neutral Rating
MT
08/04Morgan Stanley Raises Regeneron Pharmaceuticals' Price Target to $625 From $619, Mainta..
MT
08/04Gilead Sciences to Buy UK Biotech Firm MiroBio for $405 Million
MT
08/04RBC Raises Price Target on Regeneron Pharmaceuticals to $647 From $640, Maintains Secto..
MT
08/04Gilead Sciences, Inc. entered into a definitive agreement to acquire MiroBio Ltd from S..
CI
08/03Wall Street rises on tech, earnings boost as recession fears ease
RE
08/03European ADRs Nudge Higher in Wednesday Trading
MT
08/03Regeneron Pharmaceuticals Up Over 7%, on Pace for Largest Percent Increase Since June 2..
DJ
08/03Gilead Sciences Up Over 5%, on Pace for Largest Percent Increase Since January 2021 -- ..
DJ
08/03US STOCKS-Strong earnings lift Wall Street ahead of services activity data
RE
08/03TRANSCRIPT : Regeneron Pharmaceuticals, Inc., Q2 2022 Earnings Call, Aug 03, 2022
CI
08/03Regeneron Pharmaceuticals Q2 Adjusted Earnings, Revenue Decline
MT
08/03Earnings Flash (REGN) REGENERON PHARMACEUTICALS Posts Q2 Revenue $2.86B
MT
08/03Earnings Flash (REGN) REGENERON PHARMACEUTICALS Posts Q2 EPS $9.77
MT
08/03Regeneron quarterly profit slips as COVID antibody sales dry up
RE
08/03Regeneron Pharmaceuticals, Inc. Reports Earnings Results for the Second Quarter and Six..
CI
08/03Regeneron Pharmaceuticals, Inc. Announces Encouraging Initial Data from Phase 1/2 Trial..
CI
08/02Hong Kong Allows Sinovac Shots For Infants
MT
08/02Gilead Sciences Updates Fiscal Year Outlook Following 2Q Results
DJ
08/02INSIDER SELL : Regeneron Pharmaceuticals
MT
08/02INSIDER SELL : Vertex Pharmaceuticals
MT
08/02Gilead Sciences Posts Slightly Higher 2Q Sales
DJ
08/02Gilead quarterly profit falls as COVID antiviral sales decrease
RE
08/02TRANSCRIPT : Gilead Sciences, Inc., Q2 2022 Earnings Call, Aug 02, 2022
CI
08/02Gilead Sciences Q2 Adjusted EPS Drop While Revenue Gains; Company Boosts 2022 Outlook
MT
08/02Gilead Sciences, Inc. Declares Quarterly Cash Dividend for the Third Quarter of 2022, P..
CI
08/02GUIDANCE : (GILD) GILEAD SCIENCES Sees Fiscal Year 2022 EPS Range $6.35 - $6.75
MT
08/02Earnings Flash (GILD) GILEAD SCIENCES Reports Q2 Revenue $6.26B
MT
08/02Earnings Flash (GILD) GILEAD SCIENCES Posts Q2 EPS $1.58
MT
08/02Gilead Sciences, Inc. Reports Earnings Results for the Second Quarter and Six Months En..
CI
08/02EARNINGS REACTION HISTORY : Gilead Sciences, 63.6% Follow-Through Indicator, 3.0% Sensitiv..
MT
08/02Pfizer Seeks Extended Swiss Approval For COVID-19 Vaccine to Cover Omicron Protection
MT
07/29SVB Securities Adjusts BioNTech's Price Target to $224 from $223, Keeps Outperform Rati..
MT
07/29UBS Adjusts Wuxi Apptec's Price Target to HK$175 From HK$173, Keeps at Buy
MT
07/28Gilead Sciences, Inc. Announces Executive Changes
CI
07/28Gilead Sciences Says Biktarvy Treatment Shows Efficacy in Patients With HIV/Hepatitis B..
MT
1  2  3  4  5  6  7  8  9  10Next
Upcoming event on REGULUS THERAPEUTICS INC.